Objective: To study the effects of symbicort turbuhaler combined with tiotropium bromide on serum PCT, TIMP-1, MMP-9, IFN-γ, arterial blood gases and pulmonary function in patients with AECOPD. Methods A total of 90 ...Objective: To study the effects of symbicort turbuhaler combined with tiotropium bromide on serum PCT, TIMP-1, MMP-9, IFN-γ, arterial blood gases and pulmonary function in patients with AECOPD. Methods A total of 90 patients in our hospital with AECOPD during January 2014 to January 2017 were divided into the control group (n=45) and the treatment group (n=45) randomly. The control group was treated with tiotropium bromide;the treatment group was treated with symbicort turbuhaler combined with tiotropium bromide. The two groups were treated for 14 d. That was compared of the serum PCT, TIMP-1, MMP-9, IFN-γ, PaO2, SaO2, PaCO2, MPAP, PASP and PADP of the two groups before and after treatment. Results The serum PCT, TIMP-1, MMP-9, IFN-γ, PaO2, SaO2, PaCO2, MPAP, PASP and PADP of the two groups before treatment have no significantly differences. The serum PCT, TIMP-1, MMP-9 and IFN-γ levels of the two groups after treatment were significantly lower than before treatment. The serum PCT, TIMP-1, MMP-9 and IFN-γ levels of the treatment group after treatment were significantly lower than the control group. The PaO2, SaO2 of the two groups after treatment were significantly higher than before treatment, the PaCO2, MPAP, PASP and PADP of the two groups after treatment were significantly lower than before treatment. The PaO2, SaO2, PaCO2, MPAP, PASP and PADP of the treatment group after treatment were significantly better than the control group. Conclusion Symbicort turbuhaler combined with tiotropium bromide can reduce the serum PCT, TIMP-1, MMP-9, IFN-γlevels and the pulmonary arterial hypertension, improve the lung tissue oxygen supply and the cardiopulmonary function, and it was worthy clinical application.展开更多
文摘Objective: To study the effects of symbicort turbuhaler combined with tiotropium bromide on serum PCT, TIMP-1, MMP-9, IFN-γ, arterial blood gases and pulmonary function in patients with AECOPD. Methods A total of 90 patients in our hospital with AECOPD during January 2014 to January 2017 were divided into the control group (n=45) and the treatment group (n=45) randomly. The control group was treated with tiotropium bromide;the treatment group was treated with symbicort turbuhaler combined with tiotropium bromide. The two groups were treated for 14 d. That was compared of the serum PCT, TIMP-1, MMP-9, IFN-γ, PaO2, SaO2, PaCO2, MPAP, PASP and PADP of the two groups before and after treatment. Results The serum PCT, TIMP-1, MMP-9, IFN-γ, PaO2, SaO2, PaCO2, MPAP, PASP and PADP of the two groups before treatment have no significantly differences. The serum PCT, TIMP-1, MMP-9 and IFN-γ levels of the two groups after treatment were significantly lower than before treatment. The serum PCT, TIMP-1, MMP-9 and IFN-γ levels of the treatment group after treatment were significantly lower than the control group. The PaO2, SaO2 of the two groups after treatment were significantly higher than before treatment, the PaCO2, MPAP, PASP and PADP of the two groups after treatment were significantly lower than before treatment. The PaO2, SaO2, PaCO2, MPAP, PASP and PADP of the treatment group after treatment were significantly better than the control group. Conclusion Symbicort turbuhaler combined with tiotropium bromide can reduce the serum PCT, TIMP-1, MMP-9, IFN-γlevels and the pulmonary arterial hypertension, improve the lung tissue oxygen supply and the cardiopulmonary function, and it was worthy clinical application.
